Navigation Links
China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010
Date:3/5/2010

1, 2009 December 31, March 31, 2009 2009 US$ RMB RMB (in thousands except redemption value and number of shares) ASSETS Current assets Cash and cash equivalents 56,560 386,069 161,406 Accounts receivable, less allowance for doubtful accounts (December 31, 2009: RMB9,251; March 31, 2009: RMB 6,170) 8,361 57,071 49,763 Inventories 843 5,757 6,501 Prepaid expenses and other receivables 1,511 10,312 7,978 Deferred tax assets 476 3,249 1,846 Total current assets 67,751 462,458 227,494 Property, plant and equipment, net 37,553 256,331 236,740 Non-current prepayments and deposits 1,735 11,846 27,184 Non-current accounts receivable, less allowance for doubtful accounts (December 31, 2009: RMB5,390; March 31, 2009: RMB2,223) 24,007 163,872 91,761 Inventories 4,153 28,348 26,069 Intangible asset, net 3,888 26,540 27,268 Available-for-sale equity securities 8,780 59,932 26,242 Deferred reverse recapitalization costs -- -- 33,633 Deferred tax assets 89 609 -- Total assets 147,956 1,009,936 696,391 LIABILITIES Current liabilities Bank loan 6,592 45,000 -- Accounts payable 1,274 8,693 5,128 A
'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
2. China Sky One Medical to Attend Rodman & Renshaw Annual China Investment Conference
3. China Baicaotang to Attend Rodman & Renshaw Annual China Investment Conference
4. China Medical Technologies Reports Third Fiscal Quarter Financial Results
5. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
6. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
7. China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility
8. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
9. China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results
10. China Medical Technologies to Participate Investor Conferences in March 2010
11. China Biologic Products Responds to Allegations on Financial Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Study Results for Memory and Cognition Validate Clinical ... ... Amarin Corporation plc,(NASDAQ: AMRN ) ("Amarin" or "Company") announced ... using ultra-pure,eicosapentanoic acid (EPA) have been published in the "Journal ...
... Sample Analysis Systems-, PHILADELPHIA, Sept. 24 ... whole genome imaging and analytic,platforms for clinical ... the issuance of a patent for a ... The patent covers a novel technique for,the ...
... Shire management team, CAMBRIDGE, Mass., and ... SHP, Nasdaq: SHPGY, TSX: SHQ),the global specialty ... been appointed President of its Human Genetic ... than 20 years of,management, regulatory affairs, manufacturing ...
Cached Biology Technology:Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 2Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 4Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 5BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis 2BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis 3Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 2Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 3Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 4
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... new species of monkey flower, created by the union ... of a stream in Scotland. Genetic changes in this attractive yellow-flowered ... rare example of a brand new species that has originated in ... and some crops are thought to have originated in this way, ...
... Pharmaceuticals today announced that research collaborators at the Peter ... established, for the first time, that RNA Polymerase I ... and that its inhibition selectively activates p53 to kill ... the findings show that Cylene,s Pol I inhibitor, CX-5461, ...
... debilitating illnesses one can develop. Currently, the disease afflicts 6.5 ... to between 11 and 16 million, or 1 in 85 ... one to grow forgetful, confused and, eventually, catatonic. Recently approved ... consensus on the underlying mechanism of the disease. "We ...
Cached Biology News:Rare glimpse into the origin of species 2Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy 2Small molecule may play big role in Alzheimer's disease 2Small molecule may play big role in Alzheimer's disease 3Small molecule may play big role in Alzheimer's disease 4
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
fli-1...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
... 1;The Human Embryonic Stem Cell (hESC) Starter Kit ... to get started culturing hESCs as soon as ... in stem cell training courses around the world, ... these products has been extensively tested using GIBCO's ...
Biology Products: